文献速递临床试验与 GCP

瑞芬太尼用于饱胃风险患者快速序贯诱导插管非劣效性试验方案

Assessment of remifentanil for rapid sequence induction and intubation in patients at risk of pulmonary aspiration of gastric contents compared to rapid-onset paralytic agents: study protocol for a non-inferiority simple blind randomized controlled trial (the REMICRUSH study).
PubMed 文献 · Trials · 2021-03-30

REMICRUSH 研究为多中心、单盲、非劣效随机对照试验,比较瑞芬太尼(3–4 μg/kg)与快速起效肌松药(琥珀胆碱或罗库溴铵 1 mg/kg)在 1150 例全麻气管插管成人手术患者中的插管成功率。主要结局为无重大并发症的成功气管插管比例,非劣效界值 7%。

要点

  • 瑞芬太尼组剂量为 3–4 μg/kg,对照为琥珀胆碱或罗库溴铵 1 mg/kg。
  • 主要结局为无重大并发症的成功气管插管比例,非劣效界值 7%。
  • 计划纳入 1150 例成人全麻手术需气管插管且存在胃内容物误吸风险的患者。

核心结论

  • 该研究旨在证明瑞芬太尼联合催眠药在饱胃风险患者快速序贯诱导气管插管中不劣于快速起效肌松药联合催眠药。

研究设计与样本

  • 多中心、单盲、非劣效随机对照试验,比较瑞芬太尼(3–4 μg/kg)与快速起效肌松药(琥珀胆碱或罗库溴铵 1 mg/kg)。
  • 计划纳入 1150 例全麻下需气管插管且存在胃内容物误吸风险的成人手术患者,来自 15 个法国麻醉单位。
  • 主要分析包括意向性治疗和符合方案人群,非劣效界值为 7%。

关键数值与推荐

  • 瑞芬太尼剂量为 3–4 μg/kg,对照肌松药为琥珀胆碱或罗库溴铵 1 mg/kg。
  • 主要结局为无重大并发症的成功气管插管比例,非劣效界值 7%。
  • 计划样本量为 1150 例成人手术患者。

临床怎么用

  • 若结果证明非劣效,瑞芬太尼联合催眠药可作为饱胃风险患者快速序贯诱导插管的替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid-onset paralytic agents are recommended to achieve muscle relaxation and facilitate tracheal intubation during rapid sequence induction in patients at risk of pulmonary aspiration of gastric contents. However, opioids are frequently used in this setting. The study's objective is to demonstrate the non-inferiority of remifentanil compared to rapid-onset paralytic agents, in association with an hypnotic drug, for tracheal intubation in patients undergoing procedure under general anesthesia and at risk of pulmonary aspiration of gastric contents. METHODS: The REMICRUSH (Remifentanil for Rapid Sequence Induction of Anaesthesia) study is a multicenter, single-blinded, non-inferiority randomized controlled trial comparing remifentanil (3 to 4 μg/kg) with rapid-onset paralytic agents (succinylcholine or rocuronium 1 mg/kg) for rapid sequence induction in 1150 adult surgical patients requiring tracheal intubation during general anesthesia. Enrolment started in October 2019 in 15 French anesthesia units. The expected date of the final follow-up is October 2021. The primary outcome is the proportion of successful tracheal intubation without major complications. A non-inferiority margin of 7% was chosen. Analyses of the intent-to-treat and per-protocol populations are planned. DISCUSSION: The REMICRUSH trial protocol has been approved by the ethics committee of The Comité de Protection des Personnes Sud-Ouest et Outre-Mer II and will be carried out according to the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The results of this study will be disseminated through presentations at scientific conferences and publications in peer-reviewed journals. The REMICRUSH trial is the first randomized controlled trial powered to investigate whether remifentanil with hypnotics is non-inferior to rapid-onset paralytic agents with hypnotic in rapid sequence induction of anesthesia for full stomach patients considering successful tracheal intubation without major complication. TRIAL REGISTRATION: ClinicalTrials.gov NCT03960801. Registered on May 23, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Grillot N, Garot M, Lasocki S, et al. Assessment of remifentanil for rapid sequence induction and intubation in patients at risk of pulmonary aspiration of gastric contents compared to rapid-onset paralytic agents: study protocol for a non-inferiority simple blind randomized controlled trial (the REMICRUSH study). Trials. 2021. PMID: 33785069. doi:10.1186/s13063-021-05192-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。